Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study

Abstract Background The integration of transarterial chemoembolization (TACE) with systemic therapy has demonstrated improved survival outcomes in patients with unresectable hepatocellular carcinoma (HCC). However, there is limited evidence evaluating the combination of TACE with the systemic regime...

Descripción completa

Detalles Bibliográficos

Autores principales:	Lingzhan Meng, Hu Li, Yingjie Ji, Peng Yu, Zizheng Wang, Li Cao, Bin Shi, Yanling Shao, Jin Yan, Yinjie Gao, Zhenyu Zhu
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Springer 2024-11-01
Colección:	Cancer Immunology, Immunotherapy
Materias:	Combination therapy Hepatocellular carcinoma Lenvatinib Sintilimab Transarterial chemoembolization (TACE)
Acceso en línea:	https://doi.org/10.1007/s00262-024-03857-5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!